微RNA-221-3p通过调节CDKN1BB来促进燃烧后HUVEC的增殖,迁移和血管生成
Kun Miao1, Fei Xie1, JinGui Lin1
1Department of Hand and Foot Microsurgery, Fuzhou Second Hospital Affiliated to Xiamen University, Fuzhou City, Fujian Province, 350000, China.
Acta biochimica Polonica
|November 22, 2023
概括
微RNA-221-3p (miR-221-3p) 通过向CDKN1B.B.来增强受烧伤的人类静脉内皮细胞 (HUVECs) 的血管生成. 这种miR-221-3p/CDKN1B通路为烧伤治疗提供了潜在的治疗点.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 生物医学研究生物医学研究
背景情况:
- 微RNA-221-3p (miR-221-3p) 参与了血管重塑.
- 它在燃烧引起的血管生成中的具体作用尚不清楚.
- 研究miR-221-3p在烧伤中的功能对于理解血管修复至关重要.
研究的目的:
- 为了确定miR-221-3p对人静脉内皮细胞 (HUVECs) 在烧伤后的血管生成的影响.
- 阐明miR-221-3p在烧伤血管生成中的作用背后的分子机制.
- 探索miR-221-3p/CDKN1B轴作为治疗点的潜力.
主要方法:
- 使用热处理建立了一个燃烧HUVEC模型.
- 通过转染来操纵miR-221-3p和CDKN1B的表达.
- 使用MTT,殖民地形成,Transwell,流细胞计和管形成试验评估HUVEC的增殖,迁移,亡,细胞周期和管形成.
- 通过RT-qPCR和西方布洛特量化基因和蛋白质表达.
- 使用双露西法酶记者试验证实了miR-221-3p和CDKN1B的相互作用.
主要成果:
- 燃烧HUVECs表现出较低的miR-221-3p和高的CDKN1B表达.
- miR-221-3p的过度表达促进了HUVEC的增殖,迁移和管形成,同时抑制了亡和G0/G1阶段的停止.
- 过度表达CDKN1B产生了相反的效果.
- miR-221-3p knockdown 损害了血管生成,这种效应被CDKN1B knockdown 逆转.
- miR-221-3p直接针对的是CDKN1B.
结论:
- miR-221-3p通过降低CDKN1B的调节,显著增强了受烧伤的HUVECs的血管生成.
- 该miR-221-3p/CDKN1B信号通路代表了开发新型烧伤疗法的有希望的分子标.
- 针对这一轴可以改善伤口愈合和烧伤后血管再生.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K